Department of Diagnostic Innovation, Fondazione IRCCS Istituto Nazionale dei Tumori, Milan, Italy.
Department of Medical Oncology, Fondazione IRCCS Istituto Nazionale dei Tumori, Milan, Italy.
Tumori. 2024 Oct;110(5):304-308. doi: 10.1177/03008916241248007. Epub 2024 Apr 27.
The use of Digital Healthcare Products is leading to significant improvements in clinical practice. Herein, we discuss the development of PROACT 2.0 (Patient Reported Opinions About Clinical Tolerability v2.0), a novel open-source mobile and web application developed at Fondazione IRCCS Istituto Nazionale Tumori in Milan. It was developed in collaboration with The Christie, Manchester, in the context of work package 2 of the UpSMART Accelerator project, involving a consortium of referral cancer centers from the UK, Spain and Italy. PROACT 2.0 enhances communication between patients and healthcare providers in cancer clinical trials, allowing patients to report adverse events and side effects, and healthcare teams to collect valuable patient-reported outcome measures for treatment management. PROACT 2.0 supports text, audio, and video messaging, offering a secure, non-urgent communication channel that integrates with, or replaces, traditional methods. Its user-friendly and multilingual interface provides a new route for patient engagement and streamlines the handling of logistical information. Positive feedback from initial testing warrants future enhancements for broader applicability in cancer research and treatment.
数字医疗产品的应用正在引领临床实践的重大变革。在此,我们讨论了 PROACT 2.0(患者对临床耐受性的报告意见 v2.0)的开发,这是一款由米兰的 Fondazione IRCCS Istituto Nazionale Tumori 开发的新型开源移动和网络应用程序。它是在曼彻斯特克里斯蒂医院的合作下开发的,是 UpSMART 加速器项目工作包 2 的一部分,涉及来自英国、西班牙和意大利的转诊癌症中心的联盟。PROACT 2.0 增强了癌症临床试验中患者和医疗保健提供者之间的沟通,使患者能够报告不良事件和副作用,并且医疗团队可以收集有价值的患者报告的治疗管理结果措施。PROACT 2.0 支持文本、音频和视频消息传递,提供安全、非紧急的沟通渠道,可与传统方法集成或替代传统方法。其用户友好和多语言界面为患者参与提供了新途径,并简化了后勤信息的处理。初步测试的积极反馈证明了未来在癌症研究和治疗中更广泛应用的潜力。